

September 8, 2010



Quick-Med Technologies Expands IP With Fourth NIMBUS(R) Patent

Patent Protects Post-Polymerization Bonding Process

GAINESVILLE, Fla., Sept. 8, 2010 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCBB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent 7,790,217 entitled "Method of Attaching an Antimicrobial Cationic Polyelectrolyte to the Surface of a Substrate."

"This fourth patent further expands and strengthens our NIMBUS^(R) technology intellectual property by protecting the process used to bind the active agent to wound dressings and other substrates," said J. Ladd Greeno, Quick-Med's CEO. "Because NIMBUS technology is non-toxic, non-leaching and has been designed to avoid bacterial-resistance concerns, there are now antimicrobial wound dressings safe enough to apply to any wound throughout the healing cycle."

This key patent protects the process used to permanently bind a broad-spectrum, highly effective microbicide to specific substrates, as well as a very broad selection of substrate types and product applications. Post-polymerization bonding is a unique process in which the resulting material has a non-leachable microbicide firmly retained. The allowed claims of this application cover two polyelectrolyte antimicrobials: polydiallyldimethyl ammonium chloride and polyvinylbenzyltrimethyl ammonium chloride. The claims grant protection to the antimicrobial agents cleared by the FDA under *de novo* evaluation, also distinguishing the novelty of the technology.

NIMBUS is the first non-leaching antimicrobial available in a wound dressing. Other antimicrobial dressings rely on the release of biocides into the wound bed that can impede the wound healing process. NIMBUS dressings serve as a barrier to infection, kill germs

absorbed into the dressing, and do not interfere with tissue healing. NIMBUS technology works rapidly and maintains effectiveness even in the presence of large amounts of blood or other organic materials. NIMBUS is non-toxic and by design, poses minimal risk of bacteria developing resistance.

This latest patent is the fourth such recognition of propriety ownership secured by Quick-Med for the company's novel NIMBUS technology. Other patents cover applications to a broad range of substrates including textiles, medical products, filters, absorbent materials and packaging composed in whole or in part by cellulose, silk, wool and synthetics such as polyester, polyurethane, nylon and acrylics, proteins such as gelatin and collagen, rubber and others.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company focused on developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. Quick-Med commercialized its NIMBUS technology in traditional wound care products in 2009 and is now developing NIMBUS applications in several advanced wound dressing formats including adhesives, foams, hydrogels, films, and hydrocolloids. For more information, see: www.quickmedtech.com.

(C) 2010 Quick-Med Technologies, Inc. All rights reserved. NIMBUS^(R) is a registered trademark of Quick-Med Technologies, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.

Contact:

Quick-Med Technologies
J. Ladd Greeno, CEO
(888) 835.2211 Ext 102
jgreeno@quickmedtech.com
The Ruth Group
Media:
Eric Reiss
(646) 536-7032
ereiss@theruthgroup.com
Investors:
Ashleigh Barreto
(646) 536-7028

abarreto@theruthgroup.com